KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.

Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, Dirk Schadendorf, Paolo A Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Maria Arance, Jean-Jacques Grob, Barbara Ratto, Saima Rodriguez, Antonella Mazzei, Sonia Dolfi, Georgina V Long

J Clin Oncol 43(13) 1546-1552

PMID39671533
PMCIDPMC12054981
DOI10.1200/JCO.24.01124
发表日期2024-12-13
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图。
摘要

摘要

Nivolumab plus relatlimab demonstrated a statistically significant improvement in progression-free survival (PFS), along with a clinically meaningful, but not statistically significant improvement in overall survival (OS) and a numerically higher objective response rate (ORR) compared with nivolumab in the RELATIVITY-047 trial (ClinicalTrials.gov identifier: NCT03470922). We report updated descriptive efficacy and safety results from RELATIVITY-047 with a median follow-up of 33.8 months. Median PFS was 10.2 months (95% CI, 6.5 to 15.4) with nivolumab plus relatlimab and 4.6 months (95% CI, 3.5 to 6.5) with nivolumab (hazard ratio [HR], 0.79 [95% CI, 0.66 to 0.95]); median OS was 51.0 months (95% CI, 34.0 to not reached) and 34.1 (95% CI, 25.2 to 44.7) months, respectively (HR, 0.80 [95% CI, 0.66 to 0.99]). ORR was 43.7% (95% CI, 38.4 to 49.0) with nivolumab plus relatlimab and 33.7% (95% CI, 28.8 to 38.9) with nivolumab. Efficacy across the majority of prespecified subgroups favored the combination. No new or unexpected safety signals were identified. Overall, at 3-year follow-up, the benefit observed with nivolumab plus relatlimab compared with nivolumab in patients with advanced melanoma was sustained, with the OS HR 95% CI upper bound now <1. This benefit is accompanied by a safety profile consistent with previous reports.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.CONSORT diagram.
非 KM Figure
FIG 2.Kaplan–Meier estimates of (A) PFS and (B) OS. BICR, blinded independent central review; HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival.
非 KM Figure
FIG 3.(A) Response to treatment and Kaplan–Meier estimates of (B) MSS a and (C) PFS2. a A total of 375 deaths (52.5%) were reported (173 [48.7%] in the nivolumab plus relatlimab arm and 202 [56.3%] in the nivolumab arm), with 133/355 (37.5%) and 166/359 (46.2%) deaths due to melanoma reported in the nivolumab plus relatlimab arm and nivolumab arm (nonmelanoma deaths occurred in 40 patients [11.3%] and 36 patients [10.0%]), respectively. MSS was defined as the time from random assignment to death due to melanoma per investigator assessment, with deaths for any other reason, including death due to study drug toxicity, being censored. PFS2 was defined as the time from random assignment to progression after the next line of therapy, per investigator assessment, or to death from any cause, whichever occurred first. CR, complete response; HR, hazard ratio; MSS, melanoma-specific survival; NR, not reached; PD, progressive disease; PFS2, progression-free survival-2; PR, partial response; SD, stable disease.
非 KM Figure